Dysregulated TRAF3 and BCL2 Expression Promotes Multiple Classes of Mature Non-hodgkin B Cell Lymphoma in Mice.

TNF-Receptor Associated Factor (TRAF)-3 is a master regulator of B cell homeostasis and function. TRAF3 has been shown to bind and regulate various proteins involved in the control of innate and adaptive immune responses. Previous studies showed that TRAF3 overexpression renders B cells hyper-reactive to antigens and Toll-like receptor (TLR) agonists, while TRAF3 deficiency has been implicated in the development of a variety of B cell neoplasms. In this report, we show that transgenic mice overexpressing TRAF3 and BCL2 in B cells develop with high incidence severe lymphadenopathy, splenomegaly and lymphoid infiltrations into tissues and organs, which is the result of the growth of monoclonal and oligoclonal B cell neoplasms, as demonstrated by analysis of VHDJH gene rearrangement. FACS and immunohistochemical analyses show that different types of mature B cell neoplasms arise in TRAF3/BCL2 double-transgenic (tg) mice, all of which are characterized by the loss of surface IgM and IgD expression. However, two types of lymphomas are predominant: (1) mature B cell neoplasms consistent with diffuse large B cell lymphoma and (2) plasma cell neoplasms. The Ig isotypes expressed by the expanded B-cell clones included IgA, IgG, and IgM, with most having undergone somatic hypermutation. In contrast, mouse littermates representing all the other genotypes (TRAF3-/BCL2-; TRAF3+/BCL2-, and TRAF3-/BCL2+) did not develop significant lymphadenopathy or clonal B cell expansions within the observation period of 20 months. Interestingly, a large representation of the HCDR3 sequences expressed in the TRAF3-tg and TRAF3/BCL2-double-tg B cells are highly similar to those recognizing pathogen-associated molecular patterns and damage-associated molecular patterns, strongly suggesting a role for TRAF3 in promoting B cell differentiation in response to these antigens. Finally, allotransplantation of either splenocytes or cell-containing ascites from lymphoma-bearing TRAF3/BCL2 mice into SCID/NOD immunodeficient mice showed efficient transfer of the parental expanded B-cell clones. Altogether, these results indicate that TRAF3, perhaps by promoting exacerbated B cell responses to certain antigens, and BCL2, presumably by supporting survival of these clones, cooperate to induce mature B cell neoplasms in transgenic mice.

Mitochondrial DAMPs induce endotoxin tolerance in human monocytes: an observation in patients with myocardial infarction.

Monocyte exposure to mitochondrial Danger Associated Molecular Patterns (DAMPs), including mitochondrial DNA (mtDNA), induces a transient state in which these cells are refractory to further endotoxin stimulation. In this context, IRAK-M up-regulation and impaired p65 activity were observed. This phenomenon, termed endotoxin tolerance (ET), is characterized by decreased production of cytokines in response to the pro-inflammatory stimulus. We also show that monocytes isolated from patients with myocardial infarction (MI) exhibited high levels of circulating mtDNA, which correlated with ET status. Moreover, a significant incidence of infection was observed in those patients with a strong tolerant phenotype. The present data extend our current understanding of the implications of endotoxin tolerance. Furthermore, our data suggest that the levels of mitochondrial antigens in plasma, such as plasma mtDNA, should be useful as a marker of increased risk of susceptibility to nosocomial infections in MI and in other pathologies involving tissue damage.

Impaired antigen presentation and potent phagocytic activity identifying tumor-tolerant human monocytes.

Monocyte exposure to tumor cells induces a transient state in which these cells are refractory to further exposure to cancer. This phenomenon, termed "tumor tolerance", is characterized by a decreased production of proinflammatory cytokines in response to tumors. In the past, we found that this effect comprises IRAK-M up regulation and TLR4 and CD44 activation. Herein we have established a human model of tumor tolerance and have observed a marked down-regulation of MHCII molecules as well as the MHCII master regulator, CIITA, in monocytes/macrophages. These cells combine an impaired capability for antigen presentation with potent phagocytic activity and exhibit an M2-like phenotype. In addition circulating monocytes isolated from Chronic Lymphocytic Leukemia patients exhibited the same profile as tumor tolerant cells after tumor ex vivo exposition.

Growth hormone protects the intestines but not the tumour from 5-fluorouracil toxicity in the short term in the rat.

OBJECTIVE: Growth hormone has been proposed as an effective preventative treatment against radiotherapy- and chemotherapy-induced toxicity in the gut. The aim of this study was to determine whether exogenously administered growth hormone modified the effect of 5-fluorouracil on the gut and an implanted colon adenocarcinoma in the rat METHODS: An adenocarcinoma was implanted into rats that had been treated with 5-fluorouracil and growth hormone 3 days previously. Tumour growth, plus tumour and intestinal pathology, proliferation, apoptosis and p53 expression were determined. RESULTS: Growth hormone protected the intestines against 5-fluorouracil by increasing proliferation and mucosal length, and decreasing apoptosis and p53 expression. Growth hormone did not modify the effects of 5-fluorouracil on the tumour. CONCLUSIONS: Growth hormone protects the intestines from the deleterious effects of 5-fluorouracil while preserving its antitumoural action on the adenocarcinoma in the short term. Within the crypt, p53 expression is likely to be modulated by growth hormone after 5-fluorouracil treatment.

Protective effects of dietary enrichment with docosahexaenoic acid plus protein in 5-fluorouracil-induced intestinal injury in the rat.

OBJECTIVE: The intestinal side effects of anti-tumoural therapy can be so severe as to preclude its clinical efficacy, although the use of selected nutrients and growth factors may ameliorate the noxious effects. This study examines whether dietary supplementation with the polyunsaturated fatty acid docosahexaenoic acid (DHA) potentiates the protective action of growth hormone in the intestine and whether a synergetic effect occurs with dietary protein and DHA enrichment and growth hormone treatment. METHODS: Male Wistar rats were divided into nine groups and received a standard diet, or a diet supplemented with protein, or a diet supplemented with DHA, or a diet supplemented with both protein and DHA. Three days later, the rats were given 5-fluorouracil (5-FU) and treated with either growth hormone or placebo. A further group of animals fed a standard diet was not treated and served as a control group. Intestinal morphometry, proliferation and apoptosis were determined. RESULTS: Supplementing the diet with DHA prevented the negative action of 5-FU on mucosal morphometry, but protein supplementation was necessary to prevent the increased apoptosis. When growth hormone was also given with the dietary supplementation, the hypoproliferative effect of 5-FU was also prevented. CONCLUSION: Enriching the diet with DHA protects against intestinal lesions produced by the anti-tumoural drug 5-FU but requires the joint administration of supplementary protein and growth hormone to reduce the noxious effects of 5-FU.

Differential action of growth hormone in irradiated tumoral and nontumoral intestinal tissue.

Growth hormone (GH) protects the intestines from antitumoral therapy, but it is not known whether or not the tumor is also protected in vivo. The aim of the present work was to determine whether GH administration modifies the response by a colonic adenocarcinoma to radiation in vitro and in vivo. BDIX rats were implanted with a colonic adenocarcinoma and two weeks later GH treatment was started. Animals were then irradiated, and four days later samples from the intestines and tumor were taken for analysis. In vitro assays were performed in parallel to confirm the effects observed in vivo. GH reduced radiation-induced intestinal injury by improving proliferation and reducing apoptosis and p53 expression. However, tumor proliferation was reduced by GH while apoptosis and p53 expression remained unchanged. A similar response was observed in vitro. Thus, GH administration before radiotherapy protects the intestines but not the implanted adenocarcinoma in the rat.